Filling the need for trusted information on national health issues…

Blog Describes Status Of Two Experimental TB Drugs

The Center for Global Health Policy’s “Science Speaks” blog reports on the status of two experimental drugs to treat tuberculosis. “On Friday, the European Medicines Agency issued a statement refusing authorization to market [the experimental drug] delamanid for treatment of drug-resistant tuberculosis, saying the benefits of delamanid ‘had not been sufficiently shown’ [in clinical trials] and ‘did not outweigh its risks,'” the blog notes. The Treatment Action Group (TAG) “responded to the agency’s decision with a statement calling it ‘myopic and deeply disappointing,'” the blog adds. “[E]arlier this month the Maryland-based pharmaceutical company Sequella announced that it had acquired rights to develop the lagging [experimental TB treatment] sutezolid from Pfizer, which had scaled back its work on drugs for infectious diseases,” the blog writes (Barton, 7/29).

The Henry J. Kaiser Family Foundation Headquarters: 2400 Sand Hill Road, Menlo Park, CA 94025 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in Menlo Park, California.